Craniotomy Surgery — Cost, Top Hospitals & Success Rates | MyMedicPlus

A craniotomy is the foundational neurosurgical procedure in which a section of the skull (the bone flap) is temporarily removed to provide access to the brain, its coverings, and the adjacent cerebral vasculature. Unlike a craniectomy — where the bone is left out — in a craniotomy the bone flap is carefully replaced and secured with titanium plates and screws at the end of the same operation, restoring skull integrity immediately. Craniotomy is therefore a planned, controlled access procedure rather than an emergency decompression.

The operation is performed in a specialised neurosurgical theatre with the patient positioned precisely — sitting, lateral, prone, or supine — to optimise surgical approach while minimising brain retraction. The head is fixed in a three-point Mayfield head clamp. After scalp incision and elevation, high-speed drills create burr holes at the corners of the planned bone flap, and a craniotome (oscillating saw) connects them to free the flap. The dura mater is opened with microsurgical precision, and the pathology — tumour, haematoma, vascular malformation, epileptic focus, or abscess — is addressed under the operative microscope or with endoscopic assistance.

Intraoperative adjuncts that have transformed modern craniotomy include neuronavigation (GPS-like image-guided surgery using pre-operative MRI/CT data), intraoperative MRI or ultrasound to detect residual tumour, cortical and subcortical mapping to preserve eloquent function, fluorescence-guided resection using 5-ALA (a compound that makes high-grade glioma cells glow pink under blue light), and comprehensive intraoperative neurophysiological monitoring (IONM) protecting motor, sensory, visual, and language pathways.

Awake craniotomy — performed under sedation rather than full general anaesthesia — allows real-time patient participation in language, motor, or cognitive tasks during tumour resection in eloquent cortex, enabling safer, more complete removal of lesions in critical brain areas such as the speech-dominant hemisphere.

Craniotomy is the primary surgical access method for an extremely wide range of intracranial pathologies. Brain tumours — including primary gliomas (glioblastoma, astrocytoma, oligodendroglioma), meningiomas, pituitary macroadenomas with suprasellar extension, acoustic neuromas (vestibular schwannomas), metastatic lesions, and paediatric medulloblastomas — are among the most common indications. The extent of surgical resection directly correlates with survival and quality of life in glioma patients: maximum safe resection guided by neuronavigation and intraoperative mapping is the current standard of care per EANO and AANS/CNS guidelines.

Vascular conditions requiring craniotomy include cerebral aneurysm clipping, arteriovenous malformation (AVM) resection, cavernous malformation excision, and evacuation of spontaneous intracerebral haematoma. Traumatic neurosurgery uses craniotomy for acute epidural and subdural haematoma evacuation and depressed skull fracture repair. Epilepsy surgery — particularly temporal lobectomy, lesionectomy, and corpus callosotomy — relies on craniotomy to access the seizure focus identified by pre-surgical evaluation. Craniotomy is also required for brain biopsy, CSF pathway reconstruction for hydrocephalus, deep brain stimulator implantation lead placement, and spinal cord access via posterior fossa approaches.

Candidates for craniotomy are patients with confirmed intracranial pathology where surgical access is required for diagnosis, treatment, or both. The surgical decision is made by a multidisciplinary neuro-oncology, neurovascular, or epilepsy team based on lesion characteristics (size, location, mass effect, eloquence of surrounding cortex), patient neurological status, age, and performance status. Pre-operative Karnofsky Performance Scale (KPS) score and ECOG status guide surgical risk assessment. High-resolution MRI with functional sequences (fMRI, DTI tractography) maps eloquent cortex and white matter tracts adjacent to the lesion.

Contraindications include severe medical co-morbidity precluding general anaesthesia, multiple disseminated metastases where local resection would not alter overall prognosis, extremely deep-seated or brainstem lesions more accessible via stereotactic biopsy or radiosurgery, and coagulopathy requiring correction before surgery. In elderly patients or those with poor functional status, the risk-benefit ratio of craniotomy for tumour must be carefully weighed against stereotactic radiosurgery or best supportive care. For awake craniotomy, patient cooperation, psychological fitness, and ability to participate in intraoperative mapping tasks are essential prerequisites.

The surgical approach for craniotomy is anatomically tailored to the lesion location. Frontotemporal (pterional) approaches address anterior circulation aneurysms, temporal tumours, and middle fossa lesions. Frontal craniotomy accesses frontal lobe tumours, subfrontal meningiomas, and olfactory groove lesions. Parieto-occipital or occipital craniotomies are used for posterior hemisphere tumours. Posterior fossa craniotomy — the retrosigmoid and suboccipital approaches — accesses cerebellar tumours, acoustic neuromas, and posterior circulation aneurysms. Interhemispheric approaches through the corpus callosum reach deep midline tumours including thalamic and ventricular lesions.

Minimally invasive keyhole craniotomies — supraorbital eyebrow, retrosigmoid, and transcortical port-based approaches — use smaller bone openings (2–4 cm) to minimise brain exposure and scalp trauma. Tubular retractor-based minimally invasive neurosurgery (MINS) systems allow deep lesion resection through a 2 cm cortical corridor with substantially reduced approach-related morbidity. Endoscope-assisted craniotomy combines the magnification and angulation of endoscopy with the safety of open microsurgery for skull base and parasellar lesions. Intraoperative MRI suites allow immediate post-resection imaging to guide further resection within the same surgical session, improving gross total resection rates for glioma. The treating surgeon individualises the chosen technique based on patient anatomy, the extent and nature of the underlying condition, available equipment, and the balance of procedural benefit against risk — a decision made in consultation with the patient following a thorough informed consent discussion covering all available options.

For brain tumours, craniotomy with maximum safe resection extends survival and improves quality of life. In glioblastoma (GBM), gross total resection followed by the Stupp protocol (concurrent chemoradiotherapy with temozolomide) yields a median survival of 14–16 months compared with 11–12 months for biopsy alone (EORTC 2005). For meningiomas, complete (Simpson grade I) surgical resection achieves 10-year recurrence-free survival of over 80%. In cerebral aneurysm clipping, immediate aneurysm exclusion eliminates re-bleeding risk permanently, with complete occlusion rates of 95–99%.

For epilepsy surgery, temporal lobectomy achieves seizure freedom (Engel Class I) in 60–70% of carefully selected mesial temporal sclerosis patients at 2 years — far superior to ongoing anti-epileptic medication alone in drug-resistant epilepsy. Haematoma evacuation in acute subdural haematoma presenting with GCS deterioration reduces mortality from approximately 80% to 30–40% when performed within 4 hours. Awake craniotomy for tumours in eloquent cortex achieves comparable resection extents to asleep surgery while preserving language function in over 95% of patients in experienced centres.

Craniotomy carries inherent risks from operating on or adjacent to critical neural structures. New neurological deficit — motor weakness, language disturbance, visual field loss, or cognitive change — occurs in 5–20% of patients depending on lesion proximity to eloquent cortex, and is permanent in 3–10%. Surgical site infection (wound or intracranial) occurs in 2–5%; deep intracranial infection (abscess, empyema, meningitis) is less common (1–2%) but serious. Post-operative haematoma requiring re-operation occurs in 2–5%.

Seizures — both immediate and delayed — affect 15–30% of patients undergoing craniotomy for tumour, often related to cortical irritation from the surgical approach. Peri-tumoral oedema may worsen for 3–7 days post-operatively, sometimes requiring high-dose dexamethasone treatment. Cerebral venous sinus injury during surgery, particularly near the superior sagittal sinus, can cause venous infarction and haemorrhage. CSF leak through the wound or into the sinuses (rhinorrhoea or otorrhoea) occurs in 1–3% and may require revision surgery. General anaesthetic risks, deep vein thrombosis, pulmonary embolism, and pneumonia are systemic risks inherent to major neurosurgery.

Post-operative monitoring occurs in a high-dependency or neurological ICU for the first 24–48 hours, with hourly neurological observation and daily CT to detect haematoma or oedema. Patients are mobilised early — typically sitting out of bed on day 1–2 — to prevent DVT and pneumonia. Dexamethasone is tapered over 1–2 weeks to control cerebral oedema. The hospital stay ranges from 3 days for uncomplicated procedures to 2–3 weeks for complex surgeries with post-operative rehabilitation needs.

Outpatient follow-up at 6 weeks includes wound review and post-operative MRI to assess resection completeness and plan adjuvant therapy. For brain tumour patients, MRI is repeated every 2–3 months during chemoradiotherapy and every 3–6 months thereafter. Neuropsychological assessment identifies cognitive deficits requiring rehabilitation. Return to driving follows national medical fitness-to-drive guidelines — typically 6 months after craniotomy in the UK and variable across jurisdictions. Anti-epileptic medications are continued for a minimum of 3–12 months post-craniotomy and adjusted based on seizure occurrence and EEG findings.

In the United States, elective craniotomy for brain tumour resection costs USD 50,000–150,000 including surgeon fees, operating room, ICU stay, and neuronavigation. Complex skull base procedures and those requiring intraoperative MRI cost significantly more. UK private neurosurgery charges are comparable; NHS waiting times for elective procedures can extend to several months for lower-priority cases.

Leading neurosurgical centres in India provide craniotomy — including tumour resection with neuronavigation and IONM — at costs of USD 6,000–18,000, representing savings of 75–85% compared with the USA. Thai centres (Bumrungrad, Vejthani) charge USD 10,000–25,000, and Turkish centres (Acibadem, Memorial) offer similar procedures at USD 8,000–20,000. These centres hold JCI accreditation, have neurosurgeons with internationally recognised fellowship training, and operate with high-specification neuronavigation and electrophysiology equipment.

Stereotactic radiosurgery (Gamma Knife, CyberKnife, Linac SRS) is a non-invasive alternative for small (under 3 cm) benign tumours such as acoustic neuroma and meningioma, as well as single or limited brain metastases and AVMs, delivering highly focused radiation without opening the skull. For high-grade glioma in surgically inaccessible or eloquent locations, stereotactic biopsy under local anaesthesia provides tissue diagnosis without major craniotomy, followed by chemoradiotherapy.

For small or asymptomatic vascular lesions such as cavernous malformations, observation with serial MRI imaging is appropriate when surgical risk is high. Endovascular treatment (coiling, flow diverter) has largely replaced open craniotomy for most accessible cerebral aneurysms. Medical management with anti-epileptic drugs remains first-line for epilepsy before surgery is considered. For brain metastases, stereotactic radiosurgery combined with immunotherapy or targeted therapy increasingly allows deferral or avoidance of craniotomy in selected patients with controlled systemic disease.